Title: Title# Defibrotide improved outcome of monocrotaline induced rat hepatic sinusoidal
obstruction syndrome
Version: 2 Date: 20 Jun 2022
Reviewer's report:
The authors reported  their experimental study regarding the effect of defibrotide for treatment
for monocrotaline-induced sinusoidal obstruction syndrome. However, defibrotide was already
approved for medical use to treat veno-occlussive disease of the liver in the European Union
in October 2013, in the United States in March 2016, and in Australia in July 2020. Of course,
it was approved by FDA.
Title: Title# Defibrotide improved outcome of monocrotaline induced rat hepatic sinusoidal
obstruction syndrome
Version: 2 Date: 20 Jun 2022
Reviewer's report:
The authors reported  their experimental study regarding the effect of defibrotide for treatment
for monocrotaline-induced sinusoidal obstruction syndrome. However, defibrotide was already
approved for medical use to treat veno-occlussive disease of the liver in the European Union
in October 2013, in the United States in March 2016, and in Australia in July 2020. Of course,
it was approved by FDA.
Please review this paper.
user
Title: Title# Defibrotide improved outcome of monocrotaline induced rat hepatic sinusoidal
obstruction syndrome
Version: 2 Date: 20 Jun 2022
Reviewer's report:
The authors reported  their experimental study regarding the effect of defibrotide for treatment
for monocrotaline-induced sinusoidal obstruction syndrome. However, defibrotide was already
approved for medical use to treat veno-occlussive disease of the liver in the European Union
in October 2013, in the United States in March 2016, and in Australia in July 2020. Of course,
it was approved by FDA.
assistant